首页> 外文期刊>BMC Nephrology >Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
【24h】

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series

机译:利妥昔单抗治疗复发性MPO ANCA相关性血管炎并伴有严重肾脏受累的病例系列

获取原文
           

摘要

Antineutrophil cytoplasmic antibody associated vasculitis (AAV) is a group of diseases associated in most cases with the presence of anti-neutrophil cytoplasmic antibodies (ANCAs). Rituximab- based remission induction has been proven effective in ANCA associated vasculitis but scarce data exist in forms with severe renal involvement. In this case series, we report the outcomes in patients with de novo or recurrent MPO-AAV and severe renal involvement treated with rituximab without cyclophosphamide (CYC). In this single centre retrospective study, we analysed patients with a clinical diagnosis of de novo or recurrent AAV who met the following criteria: detection of P-ANCA, creatinine clearance lower than 30?ml/min, induction of remission therapy with rituximab without concomitant CYC and a follow up period of at least 6 months. The primary outcomes were complete remission after induction therapy, renal function recovery and mortality after the induction treatment. Eight patients met the inclusion criteria. The M:F ratio was 1:7, the average age was 54?years old and the median follow up was 10?months (7–72); in 2 patients there was a MPA renal limited vasculitis. A renal biopsy was performed in 7 patients. The median BVAS score at rituximab induction was 14(range 6–21). Two patients required haemodialysis before the induction treatment. Four patients developed end stage renal disease (ESRD) that required haemodialysis. These data show a remission of the disease, associated with a stabilization of the kidney function in 50% of patients. In 3 patients who did not show a response, there was also no response to CYC. This study shows a partial efficacy of rituximab in renal function recovery and a low risk of infectious complications in patients with MPO vasculitis with severe renal involvement, in particular in the short term. The optimal treatment in this subgroup of patients still has to be established because data are lacking.
机译:抗中性粒细胞胞浆抗体相关血管炎(AAV)是在大多数情况下与抗中性粒细胞胞浆抗体(ANCA)存在相关的一组疾病。基于利妥昔单抗的缓解诱导已被证明在ANCA相关性血管炎中有效,但以肾脏严重受累的形式缺乏数据。在本病例系列中,我们报道了使用环磷酰胺(CYC)的利妥昔单抗治疗的新发或复发性MPO-AAV和严重肾脏受累患者的预后。在这项单中心回顾性研究中,我们分析了符合以下标准的从头诊断或复发性AAV的临床诊断患者:检测P-ANCA,肌酐清除率低于30?ml / min,使用利妥昔单抗诱导缓解治疗但未同时发生CYC,随访期至少为6个月。主要结果是诱导治疗后完全缓解,肾功能恢复和诱导治疗后死亡率。八名患者符合纳入标准。 M:F比为1:7,平均年龄为54岁,中位随访时间为10个月(7-72); 2例患者发生了MPA肾限制性血管炎。 7例患者进行了肾脏活检。利妥昔单抗诱导时的中位BVAS评分为14(范围6–21)。两名患者在进行诱导治疗之前需要进行血液透析。四名患者发生了需要血液透析的终末期肾脏疾病(ESRD)。这些数据表明该疾病的缓解与50%的患者肾功能稳定有关。在3例未显示反应的患者中,对CYC也没有反应。这项研究表明,在严重肾脏受累的MPO血管炎患者中,尤其是在短期内,利妥昔单抗在肾功能恢复中具有部分疗效,并且感染并发症的风险较低。由于缺乏数据,仍必须确定该患者亚组的最佳治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号